We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Advisory Panel, FDA Raise Trial Concerns for Seattle’s Adcetris
Advisory Panel, FDA Raise Trial Concerns for Seattle’s Adcetris
August 3, 2011
An FDA advisory committee unanimously recommended accelerated approval for Seattle Genetics’ oncologic Adcetris to treat Hodgkin’s lymphoma (HL) and anaplastic large cell lymphoma (ALCL), but panelists and the FDA voiced concerns about the planned confirmatory studies.